Life Sciences

Is Logistics the Missing Link in Global Health?
Care Is Logistics the Missing Link in Global Health?

The staggering reality of modern medicine is that a life-saving pharmaceutical product is effectively non-existent if it remains trapped in a shipping container thousands of miles from the patient in need. While global health initiatives have made incredible strides in lowering the costs of

Can a $110 Billion Market Solve the Women's Oncology Gap?
Care Can a $110 Billion Market Solve the Women's Oncology Gap?

The global healthcare landscape is witnessing a seismic shift as dedicated investment in women’s oncology approaches an unprecedented valuation of one hundred and ten billion dollars. This massive influx of capital is not merely a financial milestone; it represents a coordinated effort to correct d

Eli Lilly and Oura Partner to Advance Connected Health Care
Data and Information Eli Lilly and Oura Partner to Advance Connected Health Care

The intersection of pharmaceutical therapy and high-precision wearable technology has moved beyond mere consumer gadgetry to become a primary pillar of modern chronic disease management. Eli Lilly’s recent strategic equity investment in Oura represents a significant shift in how healthcare p

Merck’s Lipfendra Leads a New Era of Drug Innovation
Care Merck’s Lipfendra Leads a New Era of Drug Innovation

A patient sitting at their kitchen table, casually swallowing a small white tablet, has just replaced the complex ritual of sterile needles and biological refrigeration that once defined chronic cardiovascular management. This shift represents more than a simple change in habit; it signifies the

How Can Hybrid Financing Unlock Life Sciences Growth?
Business How Can Hybrid Financing Unlock Life Sciences Growth?

The once-reliable pipeline of equity-driven venture capital has transformed into a complex web of structured deals where flexibility is now prized far above the simplicity of the traditional cash injection. Current market pressures have forced a fundamental shift in how life sciences companies

Eli Lilly Bets $2.8 Billion on Psychedelic Mental Health
Care Eli Lilly Bets $2.8 Billion on Psychedelic Mental Health

The global mental health landscape is undergoing a tectonic shift as traditional pharmaceutical giants pivot toward neuro-reductive therapies that were once relegated to the fringes of medical science. With treatment-resistant depression and post-traumatic stress disorder affecting millions of

Loading

Subscribe to our weekly news digest

Keep up to date with the latest news and events

Paperplanes Paperplanes Paperplanes
Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later